Eiger BioPharmaceuticals to focus on GLP-1 candidate, cut workforce by 25%

Paul Schloesser

Associate Editor

Eiger BioPharmaceuticals said it’s now focused on developing a GLP-1 antagonist amid a review of its business that includes laying off 25% of its employees …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Eiger BioPharmaceuticals to focus on GLP-1 candidate, cut workforce by 25%

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Pfizer CEO says opportunities with Trump ‘clearly outweigh’ the risks for pharma

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Eiger Bio­Phar­ma­ceu­ti­cals to fo­cus on GLP-1 can­di­date, cut work­force by 25%

Associate Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Eiger BioPharmaceuticals to focus on GLP-1 candidate, cut workforce by 25%